Rachel C. Nahrwold, RN

Rachel Nahrwold practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Rachel Nahrwold's NPI, 1417496696, was assigned on February 21, 2017. Rachel Nahrwold holds Florida license APRN11035656.

Rachel Nahrwold's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612. Rachel Nahrwold also practices at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., 10920 McKinley Dr, Tampa, FL 33612.

Rachel Nahrwold's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Northwell Health Physician Partners Cardiology at Great Neck. Dmand AI also links Rachel Nahrwold to 1 more breast imaging center, 1 group practice or clinic, 1 hospital outpatient department and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Rachel Nahrwold practices, 4 sites in all. Vendor and product names are available with a free account.

Nurse practitioner is Rachel Nahrwold's primary specialty in the NPI Registry, under taxonomy code 363L00000X. Rachel Nahrwold is licensed in Florida.

Dmand AI lists high cholesterol and tobacco use among the conditions Rachel Nahrwold treats.

CMS data shows 412 Medicare services from Rachel Nahrwold across 8 procedure codes in 2024, for 196 Medicare patients. Medicare paid $24,870 for them. Every service was in an office.

CMS counts 196 Medicare patients who saw Rachel Nahrwold in 2024. The largest group is 65 to 74, with 116 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 9% are also on Medicaid. Their average risk score is 0.84, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Rachel Nahrwold's median patient age at 72, with 37% women.

In 2024, Rachel Nahrwold wrote 1,827 Medicare Part D claims for 329 patients. 71% of them were for generic drugs. CMS names the drug for 1,649 of them, across 30 drugs with 11 or more claims each, at $578,945 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Rachel Nahrwold for performance year 2024, reported through an alternative payment model (APM). Rachel Nahrwold accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Rachel Nahrwold as offering telehealth.

CMS Open Payments shows 1 general payment to Rachel Nahrwold from 1 drug or device company in 2024. Food and beverage make up the largest share, 100% of the total. Amgen Inc. paid the most, $49.